144 related articles for article (PubMed ID: 25255804)
1. Rush hour traffic: directing T cells to tumor.
Neelapu SS; Kwak LW
J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25255804
[No Abstract] [Full Text] [Related]
2. Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer.
Fong L; Carroll P; Weinberg V; Chan S; Lewis J; Corman J; Amling CL; Stephenson RA; Simko J; Sheikh NA; Sims RB; Frohlich MW; Small EJ
J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25255802
[TBL] [Abstract][Full Text] [Related]
3. Sipuleucel-T in metastatic castration-resistant prostate cancer: profile report.
Plosker GL
BioDrugs; 2011 Aug; 25(4):255-6. PubMed ID: 21815700
[No Abstract] [Full Text] [Related]
4. [Therapeutic vaccines is a novel approach in castration-resistant prostate cancer treatment].
Djurhuus SS; Brasso K; Berg KD; Iversen P; Røder MA
Ugeskr Laeger; 2015 May; 177(20):. PubMed ID: 25967247
[TBL] [Abstract][Full Text] [Related]
5. New approaches to immunotherapy for metastatic castration-resistant prostate cancer.
Subudhi SK
Clin Adv Hematol Oncol; 2019 May; 17(5):283-286. PubMed ID: 31188806
[No Abstract] [Full Text] [Related]
6. Current role of immunotherapy for the treatment of prostate cancer.
Porfyris O; Kalomoiris P
J BUON; 2013; 18(4):809-17. PubMed ID: 24344002
[TBL] [Abstract][Full Text] [Related]
7. Prostate Cancer Immunotherapy with Sipuleucel-T: Current Standards and Future Directions.
Wei XX; Fong L; Small EJ
Expert Rev Vaccines; 2015; 14(12):1529-41. PubMed ID: 26488270
[TBL] [Abstract][Full Text] [Related]
8. Practical guide to immunotherapy in castration resistant prostate cancer: the use of sipuleucel-T immunotherapy.
Gomella LG; Gelpi-Hammerschmidt F; Kundavram C
Can J Urol; 2014 Apr; 21(2 Supp 1):48-56. PubMed ID: 24775724
[TBL] [Abstract][Full Text] [Related]
9. Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy.
Mulders PF; De Santis M; Powles T; Fizazi K
Cancer Immunol Immunother; 2015 Jun; 64(6):655-63. PubMed ID: 26025563
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapeutics for the treatment of prostate cancer: a patent landscape based on key therapeutic mechanisms of actions.
Harris E
Pharm Pat Anal; 2018 Jan; 7(1):47-57. PubMed ID: 29227196
[TBL] [Abstract][Full Text] [Related]
11. The evolving landscape of immunotherapy in advanced prostate cancer.
Patel VG; Oh WK
Immunotherapy; 2019 Jul; 11(10):903-912. PubMed ID: 31161846
[TBL] [Abstract][Full Text] [Related]
12. Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer.
Drake CG
J Natl Cancer Inst; 2012 Sep; 104(18):1422; author reply 1422-3. PubMed ID: 22911668
[No Abstract] [Full Text] [Related]
13. Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer.
Kantoff PW; Higano CS; Small EJ; Whitmore JB; Frohlich MW; Schellhammer PF
J Natl Cancer Inst; 2012 Jul; 104(14):1107-9; author reply 1109-12. PubMed ID: 22825556
[No Abstract] [Full Text] [Related]
14. Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer.
Gulley JL; Leitman SF; Dahut W; Schlom J
J Natl Cancer Inst; 2012 Jul; 104(14):1106; author reply 1109-12. PubMed ID: 22825555
[No Abstract] [Full Text] [Related]
15. Optimizing the efficiency and quality of sipuleucel-T delivery in an academic institution.
Davis K; Wood S; Dill E; Fesko Y; Bitting RL; Harrison MR; Armstrong AJ; Moul JW; George DJ
Clin J Oncol Nurs; 2015 Jun; 19(3):297-303. PubMed ID: 26000580
[TBL] [Abstract][Full Text] [Related]
16. [Current status and prospects of immunotherapy for castration-resistant prostate cancer].
Yatsuda J; Eto M
Nihon Rinsho; 2014 Dec; 72(12):2174-8. PubMed ID: 25518354
[TBL] [Abstract][Full Text] [Related]
17. Advances in evidence-based cancer adoptive cell therapy.
Ge C; Li R; Song X; Qin S
Chin Clin Oncol; 2017 Apr; 6(2):18. PubMed ID: 28482671
[TBL] [Abstract][Full Text] [Related]
18. Economic evaluation of sipuleucel-T immunotherapy in castration-resistant prostate cancer.
Holko P; Kawalec P
Expert Rev Anticancer Ther; 2014 Jan; 14(1):63-73. PubMed ID: 24224852
[TBL] [Abstract][Full Text] [Related]
19. Future of immunotherapy drug combinations and biomarkers.
Schmidt C
J Natl Cancer Inst; 2012 Mar; 104(6):434-9. PubMed ID: 22402694
[No Abstract] [Full Text] [Related]
20. Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
Tanimoto T; Hori A; Kami M
N Engl J Med; 2010 Nov; 363(20):1966; author reply 1967-8. PubMed ID: 21067392
[No Abstract] [Full Text] [Related]
[Next] [New Search]
